source
- FDA grants breakthrough therapy designation to Emi-Le for advanced adenoid cystic carcinomaThe U.S. Food and Drug Administration has granted breakthrough therapy designation to Emi-Le for patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). Phase 1 tri…
- Phase 1 trial shows safety and early PSA responses for novel PSMA radioligand in mCRPCA Phase 1 study evaluated the long‑circulating PSMA therapeutic radioligand [177Lu]Lu‑D‑Dan‑Phe‑PSMA in patients with metastatic castration‑resistant prostate cancer. The trial enrolled several dos…